Yue Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yue Han has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Qianwei Zhuo
6 shared publicationsJinger Lin
5 shared publicationsMin Luo
Department of Dermatology, the Union Hospital, Fujian Medical University, Fuzho, P.R. China
5 shared publicationsLihang Lin
Department of Dermatology, the Union Hospital, Fujian Medical University, Fuzho, P.R. China
4 shared publications- Min Luo
Department of Dermatology the Union Hospital, Fujian Medical University Fuzhou People's Republic of China
4 shared publications - Lihang Lin
Department of Dermatology, The Union Hospital, Fujian Medical University
3 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by National Center for Global Health and Medicine (JST) in Global Health & Medicine
- Vol. 8 (3) , 193-204
Artificial intelligence (AI)-assisted diagnosis of skin diseases: From image classification to dermatology-specific multimodal clinical reasoning
Artificial intelligence (AI) in dermatology has moved beyond the early paradigm of single-image classification. Dermatological diagnosis is achieved based on morphology, distribution, symptoms, tactile findings, temporal evolution, patient history, histopathology, and treatment response. Clinically important differentials, such as eczema versus psoriasis, cutaneous T-cell lymphoma versus chronic dermatitis, drug eruption versus viral exanthem, lupus erythematosus versus dermatomyositis, and melanoma versus atypical nevus, are rarely resolved with one photograph alone. This review therefore frames AI-assisted dermatology around a central argument: the field must progress from lesion recognition to dermatology-specific multimodal clinical reasoning. We summarize major advances in convolutional neural networks, dermoscopic benchmarks, clinical-image datasets, large language models, vision-language systems, and dermatology foundation models. We also analyze challenges that are particularly relevant to dermatology, including morphologic overlap, skin-tone bias, reduced erythema visibility on darker skin, dataset imbalance, variable smartphone imaging, imperfect reference standards, and the gap between benchmark performance and clinical deployment. Special attention is given to fairness, regulatory oversight, software as a medical device, human-AI collaboration, prognosis prediction, biologic-response modeling, longitudinal monitoring, and treatment optimization. Finally, we discuss future directions, including skin-tone-aware foundation models, lesion-level and body-site grounding, pathology-genomics integration, dermatology copilots, post-marketing surveillance, and prospective clinical trials. By prioritizing dermatological reasoning rather than generic AI architecture, this review outlines a clinically grounded pathway for building safe, interpretable, equitable, and useful AI systems for skin disease management.
- 30 June 2026
- Published by National Center for Global Health and Medicine (JST) in Global Health & Medicine
- Vol. 8 (3) , 193-204
Open AccessArtificial intelligence (AI)-assisted diagnosis of skin diseases: From image classification to dermatology-specific multimodal clinical reasoning
Artificial intelligence (AI) in dermatology has moved beyond the early paradigm of single-image classification. Dermatological diagnosis is achieved based on morphology, distribution, symptoms, tactile findings, temporal evolution, patient history, histopathology, and treatment response. Clinically important differentials, such as eczema versus psoriasis, cutaneous T-cell lymphoma versus chronic dermatitis, drug eruption versus viral exanthem, lupus erythematosus versus dermatomyositis, and melanoma versus atypical nevus, are rarely resolved with one photograph alone. This review therefore frames AI-assisted dermatology around a central argument: the field must progress from lesion recognition to dermatology-specific multimodal clinical reasoning. We summarize major advances in convolutional neural networks, dermoscopic benchmarks, clinical-image datasets, large language models, vision-language systems, and dermatology foundation models. We also analyze challenges that are particularly relevant to dermatology, including morphologic overlap, skin-tone bias, reduced erythema visibility on darker skin, dataset imbalance, variable smartphone imaging, imperfect reference standards, and the gap between benchmark performance and clinical deployment. Special attention is given to fairness, regulatory oversight, software as a medical device, human-AI collaboration, prognosis prediction, biologic-response modeling, longitudinal monitoring, and treatment optimization. Finally, we discuss future directions, including skin-tone-aware foundation models, lesion-level and body-site grounding, pathology-genomics integration, dermatology copilots, post-marketing surveillance, and prospective clinical trials. By prioritizing dermatological reasoning rather than generic AI architecture, this review outlines a clinically grounded pathway for building safe, interpretable, equitable, and useful AI systems for skin disease management.
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
The Causal Relationship Between Atopic Dermatitis and Multiple Sclerosis: A Two‐Sample Mendelian Randomization Study
Background: Existing population‐based cohort studies have been devoted to find the correlation between atopic dermatitis (AD) and autoimmune diseases including multiple sclerosis (MS). However, whether there is a causal relationship between AD and MS remains elusive. Objective: The study aims to assess the causal links between AD and MS. Methods: We utilized two‐sample Mendelian randomization (MR) analysis to investigate the causal links between AD and MS. The data for AD were obtained from a published paper. And the instrumental variables of MS are acquired from FinnGen consortium. They were selected under the three core assumptions of MR analysis. To investigate the causal relationship, we employed MR‐Egger, weighted median, inverse variance weighted (IVW), weighted mode, and simple mode for MR analysis. Sensitivity tests were performed including Cochran’s Q test to assess heterogeneity, the MR‐Egger intercept test was used to assess horizontal pleiotropy, and the leave‐one‐out test was used to assess stability. Results: The IVW results validated a causal link between AD and MS (OR = 1.376, 95% CI: 1.063–1.781, and p = 0.015). In terms of the sensitivity analyses, Cochran’s Q test showed that there was both no significant heterogeneity (IVW p = 0.628 and MR‐Egger p = 0.799) and horizontal pleiotropy ( p = 0.071). And the leave‐one‐out sensitivity test showed that there was no IV dominating the overall MR results. Conclusion: The MR analysis sheds lights on the causal role of AD on MS. AD is associated with an elevated risk of MS.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Open AccessThe Causal Relationship Between Atopic Dermatitis and Multiple Sclerosis: A Two‐Sample Mendelian Randomization Study
Background: Existing population‐based cohort studies have been devoted to find the correlation between atopic dermatitis (AD) and autoimmune diseases including multiple sclerosis (MS). However, whether there is a causal relationship between AD and MS remains elusive. Objective: The study aims to assess the causal links between AD and MS. Methods: We utilized two‐sample Mendelian randomization (MR) analysis to investigate the causal links between AD and MS. The data for AD were obtained from a published paper. And the instrumental variables of MS are acquired from FinnGen consortium. They were selected under the three core assumptions of MR analysis. To investigate the causal relationship, we employed MR‐Egger, weighted median, inverse variance weighted (IVW), weighted mode, and simple mode for MR analysis. Sensitivity tests were performed including Cochran’s Q test to assess heterogeneity, the MR‐Egger intercept test was used to assess horizontal pleiotropy, and the leave‐one‐out test was used to assess stability. Results: The IVW results validated a causal link between AD and MS (OR = 1.376, 95% CI: 1.063–1.781, and p = 0.015). In terms of the sensitivity analyses, Cochran’s Q test showed that there was both no significant heterogeneity (IVW p = 0.628 and MR‐Egger p = 0.799) and horizontal pleiotropy ( p = 0.071). And the leave‐one‐out sensitivity test showed that there was no IV dominating the overall MR results. Conclusion: The MR analysis sheds lights on the causal role of AD on MS. AD is associated with an elevated risk of MS.
- Open Access
- 27 November 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Single-cell and spatial transcriptomics reveal TNC-positive cancer-associated fibroblasts that mediate immunosuppression and promote tumor progression in basal cell carcinoma
The global incidence of basal cell carcinoma (BCC) is steadily increasing. Although immunotherapy has emerged as a treatment option, its efficacy remains l
- 27 November 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessSingle-cell and spatial transcriptomics reveal TNC-positive cancer-associated fibroblasts that mediate immunosuppression and promote tumor progression in basal cell carcinoma
The global incidence of basal cell carcinoma (BCC) is steadily increasing. Although immunotherapy has emerged as a treatment option, its efficacy remains l
- Open Access
- 7 September 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (9)
Genetic Association of Lipids and Lipid‐Lowering Drug Target Genes With Atopic Dermatitis: A Drug Target Mendelian Randomization Study
Background and Aims: Several observational studies have reported inconsistent associations between dyslipidaemia, stains use and atopic dermatitis (AD). Nevertheless, the available data on the effects of –C‐lowering as well as TG‐lowering drugs remain inconclusive and limited. The aim of this study was to evaluate the causal association of lipid traits and long‐term use of lipid‐lowering drugs on AD risk. Methods: Drug‐targeted Mendelian randomization analyses were performed in European ancestry. Pooled statistics on low‐density lipoprotein cholesterol, triglyceride and AD were extracted from large genome‐wide association studies datasets. Instrumental variables located in and around lipid‐lowering target genes were used as proxies for therapeutic inhibition of these target genes. Inverse‐variance‐weighted approach was applied as the primary analysis. Results: We explored the role of seven lipid‐lowering target genes in AD, among which genetically proxied Niemann‐Pick C1–like 1 inhibition, a target of LDL‐C‐lowering drugs, was associated with an increased risk of AD (odds ratio, 3.03; 95% CI, 1.36–6.75; p = 0.007). This association was replicated in FinnGen cohort (odds ratio, 1.72; 95% CI, 1.09–2.72; p = 0.020). A series of sensitivity analyses confirmed the robustness of the estimates. Conclusion: We found no genetic support for the repurposing of seven lipid‐lowering drug targets for the prevention of AD. However, pharmacovigilance of AD risk in Niemann‐Pick C1–like 1 inhibitor users may be warranted.
- 7 September 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (9)
Open AccessGenetic Association of Lipids and Lipid‐Lowering Drug Target Genes With Atopic Dermatitis: A Drug Target Mendelian Randomization Study
Background and Aims: Several observational studies have reported inconsistent associations between dyslipidaemia, stains use and atopic dermatitis (AD). Nevertheless, the available data on the effects of –C‐lowering as well as TG‐lowering drugs remain inconclusive and limited. The aim of this study was to evaluate the causal association of lipid traits and long‐term use of lipid‐lowering drugs on AD risk. Methods: Drug‐targeted Mendelian randomization analyses were performed in European ancestry. Pooled statistics on low‐density lipoprotein cholesterol, triglyceride and AD were extracted from large genome‐wide association studies datasets. Instrumental variables located in and around lipid‐lowering target genes were used as proxies for therapeutic inhibition of these target genes. Inverse‐variance‐weighted approach was applied as the primary analysis. Results: We explored the role of seven lipid‐lowering target genes in AD, among which genetically proxied Niemann‐Pick C1–like 1 inhibition, a target of LDL‐C‐lowering drugs, was associated with an increased risk of AD (odds ratio, 3.03; 95% CI, 1.36–6.75; p = 0.007). This association was replicated in FinnGen cohort (odds ratio, 1.72; 95% CI, 1.09–2.72; p = 0.020). A series of sensitivity analyses confirmed the robustness of the estimates. Conclusion: We found no genetic support for the repurposing of seven lipid‐lowering drug targets for the prevention of AD. However, pharmacovigilance of AD risk in Niemann‐Pick C1–like 1 inhibitor users may be warranted.
- Open Access
- 19 November 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1429709
Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis
Background: Lebrikizumab, an IL-13 immunomodulator, has shown recommendable effectiveness and safety in clinical studies for the treatment of moderate-to-severe atopic dermatitis (AD) in adolescents and adults.Objective: To evaluate the efficacy and safety of lebrikizumab in the treatment of moderate-to-severe AD through a meta-analysis.Methods: PubMed, Embase, Web of Science, Medline, and ClinicalTrials.gov databases were searched up to 8 August 2023. Randomized clinical trials of lebrikizumab treatment for moderate-to-severe AD were included by screening titles, abstracts, and papers.Results: Five studies involving 1,551 patients with AD were identified. Pooled analysis revealed significant improvements in the Eczema Area and Severity Index (EASI) score (SMD = −0.527; 95% CI = [−0.617, −0.436]), Investigator’s Global Assessment (IGA) score (RR = 2.122; 95% CI = [1.803, 2.496]), Body Surface Area (BSA) score (SMD = −0.608; 95% CI = [−1.099, −0.118]), SCORing Atopic Dermatitis (SCORAD) score (SMD = −0.441; 95% CI = [−0.633, −0.250]). Moreover, Pruritus Numeric Rating Scale (P-NRS) score, Patient-oriented Eczema Measure (POEM) scores, Sleep-loss score and Dermatology Life Quality Index (DLQI) scores showed similar results. Adverse events (AEs) (RR = 0.984; 95% CI = [0.907, 1.068]) for lebrikizumab showed no statistically significant difference compared to placebo, with similar results for serious adverse events (SAEs) (RR = 0.748; 95% CI = [0.410, 1.364]).Conclusion: This meta-analysis reveals that lebrikizumab has higher efficacy and safety in the treatment of moderate-to-severe AD, with the 250 mg Q2W dosage regimen appearing to be more advantageous.
- 19 November 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1429709
Open AccessEfficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis
Background: Lebrikizumab, an IL-13 immunomodulator, has shown recommendable effectiveness and safety in clinical studies for the treatment of moderate-to-severe atopic dermatitis (AD) in adolescents and adults.Objective: To evaluate the efficacy and safety of lebrikizumab in the treatment of moderate-to-severe AD through a meta-analysis.Methods: PubMed, Embase, Web of Science, Medline, and ClinicalTrials.gov databases were searched up to 8 August 2023. Randomized clinical trials of lebrikizumab treatment for moderate-to-severe AD were included by screening titles, abstracts, and papers.Results: Five studies involving 1,551 patients with AD were identified. Pooled analysis revealed significant improvements in the Eczema Area and Severity Index (EASI) score (SMD = −0.527; 95% CI = [−0.617, −0.436]), Investigator’s Global Assessment (IGA) score (RR = 2.122; 95% CI = [1.803, 2.496]), Body Surface Area (BSA) score (SMD = −0.608; 95% CI = [−1.099, −0.118]), SCORing Atopic Dermatitis (SCORAD) score (SMD = −0.441; 95% CI = [−0.633, −0.250]). Moreover, Pruritus Numeric Rating Scale (P-NRS) score, Patient-oriented Eczema Measure (POEM) scores, Sleep-loss score and Dermatology Life Quality Index (DLQI) scores showed similar results. Adverse events (AEs) (RR = 0.984; 95% CI = [0.907, 1.068]) for lebrikizumab showed no statistically significant difference compared to placebo, with similar results for serious adverse events (SAEs) (RR = 0.748; 95% CI = [0.410, 1.364]).Conclusion: This meta-analysis reveals that lebrikizumab has higher efficacy and safety in the treatment of moderate-to-severe AD, with the 250 mg Q2W dosage regimen appearing to be more advantageous.
- 4 September 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (1) , 155-158
Association of hidradenitis suppurativa ( HS ) with waist circumference: A bidirectional two‐sample Mendelian randomization study of HS with metabolic syndrome
Observational studies have suggested an associations between hidradenitis suppurativa (HS) and metabolic syndrome (MetS) and its components. However, it remains unclear whether the relationship is causal or not. Our study aimed to investigate the causal association of HS with MetS and its components. We performed a bidirectional, two‐sample Mendelian randomization study using summary‐level data from the most comprehensive genome‐wide association studies of HS ( n = 362 071), MetS ( n = 291 107), waist circumference ( n = 462 166), hypertension ( n = 463 010) fasting blood glucose (FBG, n = 200 622), triglycerides ( n = 441 016), and high‐density lipoprotein cholesterol (HDL‐C, n = 403 943). Genetic instrumental variables were constructed by identifying single nucleotide polymorphisms associated with the corresponding factors. The random‐effects inverse‐variance weighted method was applied as the primary method. The results showed that genetically predicted HS was positively associated with waist circumference risk in both directions. High waist circumference increased the risk of HS (odds ratio [OR] 4.147; 95% confidence interval [CI] 2.610–6.590; p = 1.746 × 10 −9 ). In addition, HS was also affected by waist circumference (OR 1.009; 95% CI 1.006–1.012; p = 3.08 × 10 −7 ). No causal relationships were found between HS and MetS or its components other than waist circumference. The findings highlight the importance of early intervention for obesity in HS patients. Further studies are needed to determine the pathophysiology of HS associated with MetS and its components.
- 4 September 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (1) , 155-158
Association of hidradenitis suppurativa ( HS ) with waist circumference: A bidirectional two‐sample Mendelian randomization study of HS with metabolic syndrome
Observational studies have suggested an associations between hidradenitis suppurativa (HS) and metabolic syndrome (MetS) and its components. However, it remains unclear whether the relationship is causal or not. Our study aimed to investigate the causal association of HS with MetS and its components. We performed a bidirectional, two‐sample Mendelian randomization study using summary‐level data from the most comprehensive genome‐wide association studies of HS ( n = 362 071), MetS ( n = 291 107), waist circumference ( n = 462 166), hypertension ( n = 463 010) fasting blood glucose (FBG, n = 200 622), triglycerides ( n = 441 016), and high‐density lipoprotein cholesterol (HDL‐C, n = 403 943). Genetic instrumental variables were constructed by identifying single nucleotide polymorphisms associated with the corresponding factors. The random‐effects inverse‐variance weighted method was applied as the primary method. The results showed that genetically predicted HS was positively associated with waist circumference risk in both directions. High waist circumference increased the risk of HS (odds ratio [OR] 4.147; 95% confidence interval [CI] 2.610–6.590; p = 1.746 × 10 −9 ). In addition, HS was also affected by waist circumference (OR 1.009; 95% CI 1.006–1.012; p = 3.08 × 10 −7 ). No causal relationships were found between HS and MetS or its components other than waist circumference. The findings highlight the importance of early intervention for obesity in HS patients. Further studies are needed to determine the pathophysiology of HS associated with MetS and its components.
- Open Access
- 10 July 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1420478
Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018–2023
Background: Tildrakizumab, the IL-23 inhibitor, is used to treat plaque psoriasis and psoriatic arthritis. Many studies have reported adverse drug reactions (ADRs) associated with Tildrakizumab.Objective: The aim of this study was to describe ADRs associated with Tildrakizumab monotherapy by mining data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).Methods: The signals of Tildrakizumab-associated ADRs were quantified using disproportionality analyses such as the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multiitem gamma Poisson shrinker (MGPS) algorithms.Results: A total of 10,530,937 reports of ADRs were collected from the FAERS database, of which 1,177 reports were identified with tildrakizumab as the “primary suspect (PS)”. Tildrakizumab-induced ADRs occurred against 27 system organ classes (SOCs). A total of 32 significant disproportionality Preferred Terms (PTs) conformed to the algorithms. Unexpected significant ADRs such as coronavirus infection, herpes simplex, diverticulitis, atrial fibrillation and aortic valve incompetence were also possible. The median time to onset of Tildrakizumab-associated ADRs was 194 days (interquartile range [IQR] 84–329 days), with the majority occurring, within the first 1 and 3 months after initiation of Tildrakizumab.Conclusion: This study identified a potential signal for new ADRs with Tildrakizumab, which might provide important support for clinical monitoring and risk prediction.
- 10 July 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1420478
Open AccessSafety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018–2023
Background: Tildrakizumab, the IL-23 inhibitor, is used to treat plaque psoriasis and psoriatic arthritis. Many studies have reported adverse drug reactions (ADRs) associated with Tildrakizumab.Objective: The aim of this study was to describe ADRs associated with Tildrakizumab monotherapy by mining data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).Methods: The signals of Tildrakizumab-associated ADRs were quantified using disproportionality analyses such as the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multiitem gamma Poisson shrinker (MGPS) algorithms.Results: A total of 10,530,937 reports of ADRs were collected from the FAERS database, of which 1,177 reports were identified with tildrakizumab as the “primary suspect (PS)”. Tildrakizumab-induced ADRs occurred against 27 system organ classes (SOCs). A total of 32 significant disproportionality Preferred Terms (PTs) conformed to the algorithms. Unexpected significant ADRs such as coronavirus infection, herpes simplex, diverticulitis, atrial fibrillation and aortic valve incompetence were also possible. The median time to onset of Tildrakizumab-associated ADRs was 194 days (interquartile range [IQR] 84–329 days), with the majority occurring, within the first 1 and 3 months after initiation of Tildrakizumab.Conclusion: This study identified a potential signal for new ADRs with Tildrakizumab, which might provide important support for clinical monitoring and risk prediction.
- Open Access
- 12 April 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (15) , e37629
The top 100 most cited articles in the treatment of basal cell carcinoma over the last decade: A bibliometric analysis and review
Basal cell carcinoma (BCC) represents the most prevalent cancer globally. The past decade has witnessed significant advancements in BCC treatment, primarily through bibliometric studies. Aiming to perform a comprehensive bibliometric analysis of BCC treatments to comprehend the research landscape and identify trends within this domain, a dataset comprising 100 scientific publications from the Web of Science Core Collection was analyzed. Country co-operation, journal co-citation, theme bursts, keyword co-occurrence, author co-operation, literature co-citation, and field-specific references were examined using VOSviewer and CiteSpace visualization tools. These articles, published between 2013 and 2020, originated predominantly from 30 countries/regions and 159 institutions, with the USA and Germany at the forefront, involving a total of 1118 authors. The keyword analysis revealed significant emphasis on the hedgehog pathway, Mohs micrographic surgery, and photodynamic therapy. The research shows developed nations are at the forefront in advancing BCC therapies, with significant focus on drugs targeting the hedgehog pathway. This treatment avenue has emerged as a crucial area, meriting considerable attention in BCC therapeutic strategies.
- 12 April 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (15) , e37629
Open AccessThe top 100 most cited articles in the treatment of basal cell carcinoma over the last decade: A bibliometric analysis and review
Basal cell carcinoma (BCC) represents the most prevalent cancer globally. The past decade has witnessed significant advancements in BCC treatment, primarily through bibliometric studies. Aiming to perform a comprehensive bibliometric analysis of BCC treatments to comprehend the research landscape and identify trends within this domain, a dataset comprising 100 scientific publications from the Web of Science Core Collection was analyzed. Country co-operation, journal co-citation, theme bursts, keyword co-occurrence, author co-operation, literature co-citation, and field-specific references were examined using VOSviewer and CiteSpace visualization tools. These articles, published between 2013 and 2020, originated predominantly from 30 countries/regions and 159 institutions, with the USA and Germany at the forefront, involving a total of 1118 authors. The keyword analysis revealed significant emphasis on the hedgehog pathway, Mohs micrographic surgery, and photodynamic therapy. The research shows developed nations are at the forefront in advancing BCC therapies, with significant focus on drugs targeting the hedgehog pathway. This treatment avenue has emerged as a crucial area, meriting considerable attention in BCC therapeutic strategies.
- 1 February 2024
- Published by SAGE Publications in Dermatitis®
- Vol. 35 (1_suppl) , S81-S90
A Retrospective Analysis of Risk Factors for Atopic Dermatitis Severity
Abstract: Background : Atopic dermatitis (AD) has the highest burden of any skin disease; however, the severity-associated factors remain unclear. Objective: To evaluate potential severity-associated factors of AD and to design and validate a severity prediction model to inform the management of AD patients. Methods: A cross-sectional study of 900 AD patients was conducted from December 2021 to October 2022 at our hospital. The primary outcome was disease severity, categorized as mild, moderate, or severe using the scoring atopic dermatitis index. Ordinal logistic regression and bootstrapped validation were used to derive and internally validate the model. Results: Increasing age, elevated eosinophil level, higher economic status, and urban residence were associated with severe AD. Breastfeeding, disinfectants and topical emollients use, and short duration of bathing were associated with mild AD. In the prediction model, predictors included age, eosinophil and economic status, residence, feeding, disinfectants and emollients use, and duration of bathing. Prediction models demonstrated good discrimination (bias-corrected concordance index [c-index] = 0.72) and good calibration. Conclusion: Risk factors for the severity of AD were identified that could aid the early prediction of AD progression. The predictive model included variables that are easily evaluated and could inform personalized prevention and therapy.
- 1 February 2024
- Published by SAGE Publications in Dermatitis®
- Vol. 35 (1_suppl) , S81-S90
A Retrospective Analysis of Risk Factors for Atopic Dermatitis Severity
Abstract: Background : Atopic dermatitis (AD) has the highest burden of any skin disease; however, the severity-associated factors remain unclear. Objective: To evaluate potential severity-associated factors of AD and to design and validate a severity prediction model to inform the management of AD patients. Methods: A cross-sectional study of 900 AD patients was conducted from December 2021 to October 2022 at our hospital. The primary outcome was disease severity, categorized as mild, moderate, or severe using the scoring atopic dermatitis index. Ordinal logistic regression and bootstrapped validation were used to derive and internally validate the model. Results: Increasing age, elevated eosinophil level, higher economic status, and urban residence were associated with severe AD. Breastfeeding, disinfectants and topical emollients use, and short duration of bathing were associated with mild AD. In the prediction model, predictors included age, eosinophil and economic status, residence, feeding, disinfectants and emollients use, and duration of bathing. Prediction models demonstrated good discrimination (bias-corrected concordance index [c-index] = 0.72) and good calibration. Conclusion: Risk factors for the severity of AD were identified that could aid the early prediction of AD progression. The predictive model included variables that are easily evaluated and could inform personalized prevention and therapy.
- 27 November 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (4) , 703-709
The causal effects of atopic dermatitis on the risk of skin cancers: A two‐sample Mendelian randomization study
Background: Observational and epidemiological studies show conflicting results on the relationship between atopic dermatitis and skin cancer. Additionally, observational studies are susceptible to the reverse causation and confounders, thus, may not interpret true causal relationships. The causal effects of atopic dermatitis on the risk of skin cancers remains unclear.Objectives: To investigate the causal relationship between atopic dermatitis and skin cancer including cutaneous malignant melanoma, cutaneous squamous cell carcinoma, basal cell carcinoma and actinic keratosis.Methods: We performed a two‐sample Mendelian randomization analysis based on summary datasets of public genome‐wide association studies of European ancestry. The inverse variance‐weighted approach was applied as the main analysis. MR–Egger and weighted median methods were used to complement the inverse variance‐weighted results. A series of sensitivity analyses were used to ensure the robustness of the causality estimates.Results: Inverse variance‐weighted method showed that genetically predicted dermatitis patients were significantly associated with an increased incidence of basal cell carcinoma (OR, 1.20; 95% CI, 1.10–1.31; p = 4.07E‐05) and cutaneous squamous cell carcinoma (OR, 1.14; 95% CI, 1.10–1.19; p = 1.05E‐11). However, we did not find a significant causality for atopic dermatitis on melanoma neither did we find actinic keratosis. Subsequent sensitive analyses supported these results.Conclusions: Our study identified the causality between atopic dermatitis basal cell carcinoma and squamous cell carcinoma. Accordingly, regular skin cancer screening is recommended for patients with atopic dermatitis.
- 27 November 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (4) , 703-709
The causal effects of atopic dermatitis on the risk of skin cancers: A two‐sample Mendelian randomization study
Background: Observational and epidemiological studies show conflicting results on the relationship between atopic dermatitis and skin cancer. Additionally, observational studies are susceptible to the reverse causation and confounders, thus, may not interpret true causal relationships. The causal effects of atopic dermatitis on the risk of skin cancers remains unclear.Objectives: To investigate the causal relationship between atopic dermatitis and skin cancer including cutaneous malignant melanoma, cutaneous squamous cell carcinoma, basal cell carcinoma and actinic keratosis.Methods: We performed a two‐sample Mendelian randomization analysis based on summary datasets of public genome‐wide association studies of European ancestry. The inverse variance‐weighted approach was applied as the main analysis. MR–Egger and weighted median methods were used to complement the inverse variance‐weighted results. A series of sensitivity analyses were used to ensure the robustness of the causality estimates.Results: Inverse variance‐weighted method showed that genetically predicted dermatitis patients were significantly associated with an increased incidence of basal cell carcinoma (OR, 1.20; 95% CI, 1.10–1.31; p = 4.07E‐05) and cutaneous squamous cell carcinoma (OR, 1.14; 95% CI, 1.10–1.19; p = 1.05E‐11). However, we did not find a significant causality for atopic dermatitis on melanoma neither did we find actinic keratosis. Subsequent sensitive analyses supported these results.Conclusions: Our study identified the causality between atopic dermatitis basal cell carcinoma and squamous cell carcinoma. Accordingly, regular skin cancer screening is recommended for patients with atopic dermatitis.